Business
Formal Grant of US Patent
Futura Medical plc has been granted a US continuation patent, No. 12,576,152, by the US Patent Office, providing protection for Eroxon® and the women's product WSD4000 until 2040. This patent grant is expected to trigger a US$2.5 million milestone payment from Haleon under their existing licence agreement, which is a significant positive development for the company. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n18 March 2026\nFutura Medical plc\n(\"Futura\", \"the Group\" or the \"Company\")\nFormal Grant of US Patent \n \nFurther to its announcement on 5 February 2026, Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to announce that the US Patent Office has formally granted its US continuation patent No. 12,576,152 which will provide additional protection for Eroxon® (including formulation derivatives such as the Eroxon® Intense formulation) and women's product WSD4000 (currently in development) until 2040 in the US.\n \nUnder the terms of its existing licence agreement with Haleon, the granting of this patent is expected to trigger a US patent milestone payment of US$2.5 million.\n \n\nContacts:\n\n\n\n\nFutura Medical plc\n \n \n\n\nAlex Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\n \n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTurner Pope Investments (TPI) Ltd - Broker\n\n\nGuy McDougall, Andrew Thacker\n\n\n+44 (0)20 3657 0050\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett, Sam Modlin, Sarah Peters\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors:\n \nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.\n \nSexual health issues are prevalent in both men and women. Erectile Dysfunction (\"ED\") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional...